SecBot SecBot

STVN

Stevanato Group S.p.A.
NYSE· Surgical & Medical Instruments & Apparatus· CIK 0001849853 Healthcare & Medical Devices
$19.45 −0.43 (−2.16%)
Oct 27 4:00 PM ET · prev $19.88
Market cap
$5.3B
Mid cap
Consensus
Buy
78% Buy or better · 18 analysts
Median target
$25.00
+29% · range $21.00–32.00
Next earnings
Nov 3
in 7 days
1 year
−25.1%
from $25.98 · Oct 27
30 days
−9.2%
from $21.41
52-week range
$13.43–25.98
−25% from high · low Mar 27
Avg volume 20D
343.1K
Oct 22 spike 961.5K
Short interest
🔒 Subscribers only
Insider net
−$561.8K
0 buyers · 8 sellers · 12 mo
New fund stakes
1
Q2 2026 13F · 0 exits
Filing reports
4
analyzed by SecBot
SecBot read BULLISH 3 reports · 90 days
Balance 0 bearish · 1 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 3/3 ·Next Earnings date, Nov 3, 2026
Strongest NEUTRAL Stevanato Group reported Q2 2026 revenue of €302 million (+8% YoY) and adjusted EBITDA of €78.7 million…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

  • S Jun 15 4 insiders sell $102.1K at $17.09
  • A Jun 16 TD Cowen initiates
  • S Aug 7 3 insiders sell $166.3K at $20.09
  • S Sep 28 1 insider sell $293.5K at $21.50

Signal stack

Where each data set points today.

  • InsidersBEARISH

    8 insiders sold $561.8K.

  • InstitutionsMIXED

    Q2 2026: 9 added (1 new), 13 trimmed or exited. Largest new: Wellington Management Group $22.6M.

  • AnalystsBULLISH

    14 of 18 rate it Buy or better. Every target is above the price.

  • TrendDOWNTREND

    6% below its 50-day average.

Who's buying

13F· Q2 2026
1
new positions
0
exits
$22.6M
in new stakes
FundMoveSharesValue
Neuberger Berman Group LLCADD5,622,269$101.6M
CREDIT AGRICOLE S ADOUBLED1,297,755$23.5M
WELLINGTON MANAGEMENT GROUP LLPNEW1,251,844$22.6M
NEW YORK STATE COMMON RETIREMENT FUNDADD791,838$14.3M
First Eagle Investment Management, LLCDOUBLED611,286$11.0M
Squarepoint Ops LLCDOUBLED193,311$3.5M
ENVESTNET ASSET MANAGEMENT INCADD181,942$3.3M
MILLENNIUM MANAGEMENT LLCTRIM155,586$2.8M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

18 analysts
Buy 78% rate it Buy or better
Strong Buy7Buy7Hold4Sell0Strong Sell0
12-month targets · 12 analysts

Price is below the lowest target. Median implies +29%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Sep 9, 2026UBS
MAINTAIN
MAINTAINNeutral
Jun 16, 2026TD Cowen
INITIATE
INITIATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$561.8K
sold · 8 insiders
DateInsiderTypeValue
Sep 28, 2026
Stocchi Mauro
See Remarks
SELL$293.5K
Aug 7, 2026
Santel Luciano
Director
SELL$40.6K
Aug 7, 2026
Dal Lago Marco
Chief Financial Officer
SELL$84.6K
Aug 7, 2026
Magistretti Elisabetta
Director
SELL$41.1K
Jun 15, 2026
FEDERICI WILLIAM J
Director
SELL$25.5K
Jun 15, 2026
Flynn Karen
Director
SELL$25.5K
Jun 15, 2026
MOREL DONALD E JR
Director
SELL$25.5K
Jun 15, 2026
Balachandran Madhavan
Director
SELL$25.5K

Earnings setup

Estimates
Nov 3
reports in 7 days

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 28, 2026 Insider
Stocchi Mauro sold 13,649 shares
See Remarks @ $21.50 ($293.5K)
Aug 10, 2026 SEC
Three STVN insiders (CFO and two directors) sold a combined $166K in open-market transactions on August 7, 2026. The…
CLUSTER — Impact 2/10
Aug 7, 2026 Insider
Santel Luciano sold 2,023 shares
Director @ $20.09 ($40.6K)
Aug 7, 2026 Insider
Dal Lago Marco sold 4,209 shares
Chief Financial Officer @ $20.09 ($84.6K)
Aug 6, 2026 SEC
Stevanato Group reported Q2 2026 revenue of €302 million (+8% YoY) and adjusted EBITDA of €78.7 million (+21%), in…
6-K — Impact 5/10
Aug 4, 2026 SEC
Stevanato Group reported Q2 2026 revenue of €302M, up 8% YoY, driven by 9% growth in BDS and 16% growth in high-value…
6-K — Impact 5/10
Aug 4, 2026 Earnings calendar
STVN Q2 2026 Earnings Before Market Open — 2026-08-04
Jun 30, 2026 Inst.
Neuberger Berman Group LLC — ADD
5,622,269 shares ($101.6M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 3, 2026
Earnings date
STVN Q3 2026 Earnings Before Market Open — 2026-11-03
Recent
Aug 4, 2026
Earnings date
STVN Q2 2026 Earnings Before Market Open — 2026-08-04
May 7, 2026
Earnings date
STVN Q1 2026 Earnings Before Market Open — 2026-05-07
Mar 18, 2026
FDA
Disopyramide Phosphate
Mortality In the National Heart, Lung and Blood Institute's Cardiac Arrhythmia Suppression Trial (CAST), a long-term, multi-center, randomized, double
Mar 13, 2026
Clinical Trial
Bupivacaine Alone vs Bupivacaine With Tramadol in Local Anesthesia Procedures
Phase 3 · COMPLETED
Mar 4, 2026
Earnings date
STVN Q4 2025 Earnings After Market Close — 2026-03-04

SecBot reports

4 filings · 1 bullish · 0 bearish · 3 neutral
All STVN filing & press-release reports (4)